User:Stellatarum/Emergent BioSolutions

From Wikipedia, the free encyclopedia
Emergent BioSolutions
IndustryPharmaceuticals, Healthcare
Founded2004
FounderFuad El-Hibri
Headquarters
Rockville, Maryland
Key people
CEO Fuad El-Hibri, President & COO Daniel J. Abdun-Nabi
ProductsBioThrax® (Anthrax Vaccine Adsorbed)
RevenueIncrease US$257.90 million (2010)[1]
Increase US$51.7 million (2010)[1]
Websitewww.emergentbiosolutions.com

Emergent BioSolutions (NYSE: EBS) is a multinational biopharmaceutical company headquartered in Rockville, Maryland. Emergent develops vaccines and therapeutics targeting infectious diseases, oncology and autoimmune disorders. The company was founded as BioPort Corporation in 1998 and became Emergent BioSolutions in 2004. Since the early 2000s, Emergent has expanded its product development, including research and development of products through joint ventures.

Overview[edit]

Emergent BioSolutions focuses on the development and manufacture of vaccines and therapeutics for the prevention or treatment of disease.[2] Fuad El-Hibri is the chairman and CEO of Emergent BioSolutions[3] and has led the company since it was founded as BioPort Inc. in 1998.[4][5] The company's headquarters is in Rockville, Maryland.[6]

History[edit]

In 1998, the BioPort Corporation was founded to acquire an anthrax vaccine manufacturing facility in Lansing, Michigan, and other assets of the Michigan Biologics Products Institute, formerly owned by the Michigan Department of Public Health.[4] In addition to the Lansing facility, BioPort acquired the license to produce anthrax vaccine for the U.S. Department of Defense.[7] After corporate restructuring in 2004, BioPort and its subsidiary Antex Biologics became wholly-owned subsidiaries of Emergent BioSolutions Inc.[8] In November 2006, Emergent held its initial public offering (IPO) on the New York Stock Exchange.[9]

Product development[edit]

In 2006 and 2007, Emergent had carried out development of medications and vaccines for the treatment of typhoid, hepatitis B and streptococcus,[6][10] for which development is no longer being pursued.[11] As of July 2011, Emergent's product development pipeline includes product candidates targeting infectious diseases, oncology and autoimmune disorders.[11]

BioThrax (Anthrax Vaccine Adsorbed)[edit]

BioThrax (Anthrax Vaccine Adsorbed) is a vaccine licensed by the U.S. Food and Drug Administration.[12] Following a study by scientists from the Centers for Disease Control and Prevention,[13] on December 19, 2008, Emergent received final FDA licensing for use of BioThrax five doses for intramuscular injection.[14] On February 11, 2009, the company announced that it had been granted a license to distribute BioThrax in India.[15] Later in 2009, Emergent received approval from the FDA to extend the shelf life of its anthrax vaccine from three to four years.[16] In 2011, BioThrax was approved for sale in Singapore by the Singapore Health Sciences Authority.[17]

Acquisitions[edit]

Emergent has added to its product pipeline through the acquisition of other biotechnology and pharmaceutical companies, including Antex Biologics Inc., a pharmaceutical research and development company, in 2003,[18] and Microscience Ltd. (based in the United Kingdom) in 2005.[19] In August 2006, Emergent purchased Vivacs GmbH, a biotechnology company based in Munich, Germany.[20] On March 6, 2008, Emergent completed the acquisition of a group of anthrax monoclonal antibodies from Avanir Pharmaceuticals.[21] On May 5, 2008, Emergent acquired patents and processes of VaxGen, Inc., of Livermore, California, including VaxGen's anthrax vaccine program.[22][23] Emergent acquired Trubion Pharmaceuticals Inc. in October 2010, providing Emergent with oncology and autoimmune disease treatment candidates.[24] In 2011, it acquired the rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy from TenX BioPharma, Inc.[25]

References[edit]

  1. ^ a b "Emergent BioSolutions Reports Financial Results for Full Year 2010". Reuters.com. Reuters. 10 March 2011. Retrieved 11 July 2011.
  2. ^ "Emergent BioSolutions Secures Orphan Drug Designation for Its Investigational Monoclonal Antibody for the Treatment of Inhalation Anthrax". Health & Beauty Close-Up. 9 November 2010.
  3. ^ Shapiro, Andy (29 May 2008). "Md. firm to buy Protein Sciences". New Haven Register.
  4. ^ a b "Lansing laboratory may begin anthrax vaccine shipments". The Michigan Daily. 23 January 2002. Retrieved 30 June 2011.
  5. ^ "Emergent BioSolutions CEO joins board of U.S. Chamber of Commerce". Washington Business Journal. 13 June 2010.
  6. ^ a b Ramstack, Tom (16 October 2007). "BioSolutions posts healthy progress". The Washington Times. p. C10.
  7. ^ Williams, Thomas D. (18 May 2001). "Shays: Pentagon Acted Inappropriately". The Hartford Courant. Retrieved 30 June 2011.
  8. ^ "Antex Biologics Awarded NIAID Grant to Continue Development of Helicobacter pylori Vaccine". BusinessWire. 9 July 2004. Retrieved 5 July 2011.
  9. ^ Cowan, Lynn (15 November 2006). "Stock of vaccine maker has weak opening after IPO". Dow Jones Newswires. The Associated Press.
  10. ^ "Form S1/A Emergent BioSolutions Inc" (PDF). Corporate IR.net. Thomson Reuters. 30 October 2006. Retrieved 20 July 2011.
  11. ^ a b "Emergent BioSolutions Portfolio as of July 2011" (PDF). Emergent BioSolutions. July 2011. Retrieved 11 July 2011.
  12. ^ Echols, Tucker (14 July 2010). "Emergent BioSolutions wins $107M HHS contract". Washington Business Journal.
  13. ^ Lauerman, John (30 September 2008). "Emergent's Anthrax Vaccine Effective With Fewer Doses in Study". Bloomberg. Retrieved 11 July 2011.
  14. ^ "Emergent BioSolutions Gets FDA Nod For Anthrax Vaccine supplemental BLA - Update". RTT News. 19 December 2008. Retrieved 11 July 2011.
  15. ^ "Local Briefing". The Washington Post. 13 February 2009. Retrieved 11 July 2011.
  16. ^ "Emergent BioSolutions Receives FDA Approval Extending Shelf Life of BioThrax (Anthrax Vaccine Adsorbed) to 4 Years". Business Wire. 10 June 2009. Retrieved 11 July 2011.
  17. ^ Clabaugh, Jeff (24 June 2011). "Emergent gets entry to Singapore". Washington Business Journal. Retrieved 22 July 2011.
  18. ^ "BioPort Corporation Completes Purchase of Assets of Antex Biologics". BusinessWire. 3 June 2003. Retrieved 5 July 2011.
  19. ^ "Emergent acquires vaccine company". BIOTECH Patent News. 1 June 2005. ISSN 0898-2813.
  20. ^ "Emergent BioSolutions Expands Presence in Germany". PR Newswire US. 3 August 2006.
  21. ^ "Avanir Divests Anthrax mAb Program to Emergent BioSolutions in Deal Worth $1.75M". Genetic Engineering & Biotechnology News. 6 March 2008. Retrieved 12 October 2011.
  22. ^ "VaxGen sells anthrax vaccine candidate to Emergent BioSolutions". Forbes. Thomson Reuters. 5 May 2008. Retrieved 11 July 2011.
  23. ^ "VaxGen wraps up sale of anthrax assets". San Francisco Business Times. 5 May 2008. Retrieved 11 July 2011.
  24. ^ "Emergent BioSolutions Completes Acquisition Of Trubion Pharmaceuticals". The Street. 28 October 2010. Retrieved 12 July 2011.
  25. ^ "Emergent BioSolutions Continues Expansion into Cancer with mAb Acquisition from TenX". Genetic Engineering & Biotechnology News. 6 June 2011. Retrieved 22 July 2011.

External links[edit]


Category:Biotechnology companies Category:Pharmaceutical companies Category:Pharmaceutical companies of the United States

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Stellatarum/Emergent_BioSolutions&oldid=455404785"